Bone Therapeutics

Rue Granbonpré 11
1435 Mont-Saint-Guibert
BE
Bone Therapeutics
Foundation date
22/06/2006
Sector
#Biotechnology - TherapeuticsSubsector
Therapeutic areas
Bone Therapeutics is a leading cell therapy company addressing high unmet medical needs in the field of orthopaedics and bone diseases.
Bone Therapeutics has a broad, diversified portfolio of bone cell therapy solutions and viscosupplement in clinical development across a number of disease areas targeting markets with large unmet medical needs and limited innovation. Our technology is based on a unique, proprietary approach to bone regeneration which turns undifferentiated stem cells into “osteoblastic”, or bone-forming cells. These cells can be administered via a minimally invasive procedure, avoiding the need for invasive surgery.
Our primary clinical focus is ALLOB ® , an allogeneic “off-the-shelf” cell therapy product derived from stem cells of healthy donors, which is in Phase II studies for the treatment of delayed-union fractures and spinal fusion. In addition, Bone Therapeutics is also developing an enhanced viscosupplement, JTA-004, for the treatment of knee osteoarthritis.
Bone Therapeutics is also conducting preclinical research on next generation products such as combined cell-matrix products for large bone defects and maxillofacial applications.
Upcoming events
All events-
0106 '23
KNOWLEDGE FOR GROWTH 2023
Event by: flanders.bio -
0506 '23
BIO International Convention 2023
Event by: Biotechnology Innovation Organisation -
0604 '23
Innovation for Health 2023
Event by: Hyphen Projects
Latest news
More news-
Bimekizumab Phase 3 data in hidradenitis suppurativa show clinically meaningful, deep and maintained response over 48 weeks
Monday March 20th 2023
Read more
-
VIB launches Data Core to support life sciences research
Thursday March 16th 2023
Read more
-
Aitia and UCB announce strategic drug discovery collaboration in Huntington's Disease
Thursday March 16th 2023
Read more
Jobs
More jobs-
21/03/23
Flemish Brabant
PhD position - Improved cytogenomic diagnosis in lymphoma: opportunities of optical genome mapping and long-read sequencing.
Temporary
KU Leuven -
21/03/23
Antwerp
Valorisation Manager for the IOF consortium IMARK, IOF platform for image-based biomarkers
Permanent
University of Antwerp -